Relational Agents in Cervical Cancer Education (RACE) (RACE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults aged 18 and older
- Patients with an ICD9 diagnosis of cervical/vaginal/vulvar cancer or dysplasia receiving care at Karmanos Cancer Institute or OU Health Stephenson Cancer Center
Exclusion Criteria:
- Patients who are recorded in the EHR as requesting to be removed from research
- Non-English speakers
- Any cognitive disability that prevents informed consent
- Any individual recruited in previous phases of the Study will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
The intervention group will be shown an educational video
|
A video about HPV and vaccines on a tablet provided by a research assistant
|
|
Active Comparator: Control
The control group will be given a standardized handout
|
A standardized handout on HPV and vaccine education will be given
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participation Rate
Time Frame: Up to 6 weeks
|
The Ratio of the number of participants to the number of patients asked to join the clinical trial
|
Up to 6 weeks
|
|
Survey Completion Rate
Time Frame: Up to 6 Weeks
|
The Ratio of the number of participants who complete the survey to the number of participants overall.
|
Up to 6 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in intention to discuss HPV vaccination
Time Frame: Up to 6 weeks
|
Changes from pre to post/follow up on intervention survey
|
Up to 6 weeks
|
|
Change in Health Literacy
Time Frame: Up to 6 weeks
|
Changes in knowledge of HPV virus and prevention from pre to post/follow up survey
|
Up to 6 weeks
|
|
Change in social norms and behaviors
Time Frame: Up to 6 weeks
|
Changes in social norms and behavioral control measures from pre and post/follow-up survey
|
Up to 6 weeks
|
|
Change in Stigma
Time Frame: Up to 6 weeks
|
Changes in stigma measures in pre and post/follow up surveys
|
Up to 6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Radhika Gogoi, M.D. PhD, Karmanos Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Vaginal Diseases
- Neoplasms, Squamous Cell
- Vulvar Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Vulvar Neoplasms
- Vaginal Neoplasms
- Papilloma
Other Study ID Numbers
Other Study ID Numbers
- 2020-031
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.